Aura Biosciences Inc (AURA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aura Biosciences Inc (AURA) has a cash flow conversion efficiency ratio of -0.279x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.89 Million) by net assets ($107.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Aura Biosciences Inc for the company's overall valuation and market capitalisation.
Aura Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Aura Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aura Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aura Biosciences Inc ranked by their cash flow conversion efficiency. See AURA debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Neogen Chemicals Limited
NSE:NEOGEN
|
-0.302x |
|
Latitude Group Holdings Ltd
AU:LFS
|
-0.165x |
|
Teyi Pharmaceutical Group Co Ltd
SHE:002728
|
0.029x |
|
Anhui Korrun Co Ltd
SHE:300577
|
0.084x |
|
REVO INSURANCE SPA O.N.
F:H0O
|
N/A |
|
Once Upon a Farm, PBC
NYSE:OFRM
|
0.054x |
|
Hubei Biocause Heilen Pharmaceutical Co. Ltd.
SHE:301211
|
0.005x |
|
Community West Bancshares
NASDAQ:CWBC
|
0.018x |
Annual Cash Flow Conversion Efficiency for Aura Biosciences Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Aura Biosciences Inc from 2019 to 2025. View AURA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $136.91 Million | $-84.74 Million | -0.619x | -17.86% |
| 2024-12-31 | $151.97 Million | $-79.81 Million | -0.525x | -85.76% |
| 2023-12-31 | $225.85 Million | $-63.85 Million | -0.283x | -1.26% |
| 2022-12-31 | $195.58 Million | $-54.60 Million | -0.279x | -31.20% |
| 2021-12-31 | $152.31 Million | $-32.41 Million | -0.213x | +83.06% |
| 2020-12-31 | $19.36 Million | $-24.32 Million | -1.256x | -86.97% |
| 2019-12-31 | $30.76 Million | $-20.67 Million | -0.672x | -- |
About Aura Biosciences Inc
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the … Read more